$NVTA Sequencing companies Q3 Rev growth yoy: Personalis - 12% Sema4 - 12% Myriad - 15% Genedx (now Okpo Health) - 19% Guardant Health - 27% Exas - 39% (non-covid products) NTRA - 61% NVTA - 67% I get it the Opex is really high right now. But they've acquired like 9 companies over the last two years that do little to no revenue. So of course cash burn is gonna be high right now. Margin improvements coming next year
11
6
6 Likes